MiNK Therapeutics (MiNK Therapeutics) YoY EBITDA Growth : 36.26% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is MiNK Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. MiNK Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 36.26%.

MiNK Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was $-0.11.

MiNK Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for MiNK Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiNK Therapeutics YoY EBITDA Growth Chart

MiNK Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

44.30

-124.59

15.73

27.84

MiNK Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial												21.92	19.74	36.44	31.90	36.26

MiNK Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

MiNK Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-0.661	-	-0.916)	/	\| -0.916 \|
=	27.84 %

MiNK Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2023 ))	/	\| EBITDA per Share (Q: Mar. 2023 )) \|
=	(-0.109	-	-0.171)	/	\| -0.171 \|
=	36.26 %

MiNK Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of MiNK Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

MiNK Therapeutics (MiNK Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiNK Therapeutics Inc (NAS:INKT) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

149 Fifth Avenue, Suite 500, New York, NY, USA, 10010

Website

https://www.minktherapeutics.com

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses.

Executives

Agenus Inc	10 percent owner	3 FORBES ROAD, LEXINGTON MA 02421
Garo H Armen	director	3 FORBES ROAD, LEXINGTON MA 02421
Ulf Wiinberg	director
Brian Corvese	director	C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Christine M Klaskin	officer: Treasurer	3 FORBES ROAD, LEXINGTON MA 02421
Jennifer Buell	director, officer: See Remarks	3 FORBES ROAD, LEXINGTON MA 02421
Barbara Ryan	director	22 CAVRAY ROAD, NORWALK CT 06855
Walter Md Flamenbaum	director	3 FORBES ROAD, LEXINGTON MA 02421
John Baldoni	director	3 FORBES ROAD, LEXINGTON MA 02421
Peter Behner	director	3 FORBES ROAD, LEXINGTON MA 02421
Van Dijk Marcus Antonius	officer: Chief Technology Officer	149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010